aPROMISE
aPROMISE is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification, and reporting of digital medical images.1
- Intracranial Hemorrhage
- Triage
- Non-Contrast
- Head
- CT
The Prevalence of Prostate Cancer2
About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Prostate cancer is the most common cancer in American men the second leading cause of cancer death in men. The prostate cancer death rate declined by about half from 1993 to 2013, most likely due to earlier detection and advances in treatment.
Support Nuclear Medicine1
The aPROMISE system is intended to be used with images acquired using nuclear medicine (NM) imaging, using PSMA PET/CT. The device provides general Picture Archiving and Communications System (PACS) tools as well as a clinical application for oncology including marking of regions of interest and quantitative analysis.
Greater consistency, compared to manually generated values.3
Consistency. Efficiency.
Diagnostic Accuracy.
Enhance the reproducibility and reliability among the readers.1
91.5 % sensitivity of regional lymph node detection 86.7% for bone.1
Enable detection and volumetric quantification of disease burden in PSMA PET/CT images.4,5
1EXINI. ePROMISE. EU User Guide PRA3152-v.15. Accessed July 2023.
2American Cancer Society. Key Statistics for Prostate Cancer. Accessed July 2023.
3Johnsson K, Brynolfsson J, Sahlstedt H, et al. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging. 2022;49(3):1041-1051. doi:10.1007/s00259-021-05497-8
4Nickols N, Anand A, Johnsson K, et al. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of aTumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer. J Nucl Med. 2022;63(2):233-239. doi:10.2967/ajnumed.120.261863
5aPROMISE IFU
Currently not available within the Calantic Viewer.
